Form 4: Capricor Therapeutics Executive Trades Shares

Karen Krasney, EVP and General Counsel of Capricor Therapeutics, Inc., reported transactions involving the purchase and sale of company common stock, executed under a Rule 10b5-1 trading plan.

Summary

• Karen Krasney, Executive Vice President and General Counsel of Capricor Therapeutics, Inc., engaged in several transactions involving the company's common stock on June 22, 2026, and June 24, 2026.
• On June 22, 2026, Krasney purchased 500 shares of common stock at $3.18 per share and sold 500 shares at $30 per share. Following these transactions, she beneficially owned 30,547 shares directly.
• On June 24, 2026, Krasney purchased an additional 400 shares at $3.18 per share and sold 400 shares at $30 per share. Her direct beneficial ownership remained at 30,547 shares after these trades.
• The sales were conducted under a Rule 10b5-1 trading plan adopted in December 2025, which is intended to satisfy affirmative defense conditions for insider trading.
• Additionally, the filing notes that stock options held by Krasney vest monthly, with a portion vesting on the first day of each month since February 1, 2022.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were conducted under a pre-defined plan, balancing insider activity with regulatory compliance.

Positives

• The executive's transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating adherence to compliance protocols.
• The executive demonstrated continued investment in the company through share purchases at a lower price point ($3.18) on the same days shares were sold at a higher price ($30).

Negatives

• A significant number of shares were sold at a much higher price ($30) compared to the purchase price ($3.18), suggesting a realization of gains by the executive.
• The filing does not provide context for the rationale behind the specific timing or volume of these trades beyond the existence of the 10b5-1 plan.

Risks

• The sale of a substantial number of shares, even under a 10b5-1 plan, could be interpreted negatively by the market, potentially impacting investor sentiment.
• The significant difference between the purchase and sale prices might raise questions about the executive's valuation of the stock at different points in time.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• Shares vested 1/48th on the first day of each month commencing February 1, 2022.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders. The execution of trades under a Rule 10b5-1 plan is a common practice to allow executives to diversify holdings or manage personal finances while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders may observe these transactions, but the Rule 10b5-1 plan mitigates concerns about opportunistic insider trading.
• Employees may view the executive's continued purchases as a sign of confidence in the company's future, despite the sales.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Capricor Therapeutics, Karen Krasney, Rule 10b5-1, Beneficial Ownership, Common Stock, Stock Options